COVID waves and anxiety; Advice on prolonged bereavement disorders; Psychiatric hospital for Egg Tosser

0

Average anxiety severity scores increased 13% from August to December 2020 among American adults, but then fell 26.8% from December 2020 to June 2021, according to new data from the CDC, depression following a similar pattern from top to bottom. However, these estimates were captured before the Delta Wave and were still higher than the 2019 numbers. (Morbidity and Mortality Weekly Report)

The American Psychiatric Association has released new tips for understanding prolonged grief disorder – a condition recently added to the Diagnostic and Statistical Manual of Mental Disorders (DSM).

A small survey of women found that many women felt screening for perinatal depression was ineffective, with the main reasons listed being that providers did not explain the purpose or uses of the screening tool, did not explain the purpose or uses of the screening tool. did not tell patients anything about the results and did not provide any follow-up. (Health affairs)

People with allergies – including asthma, atopic dermatitis, and hay fever – tended to have higher prevalences of depression, anxiety, bipolar disorder, or neuroticism. “Establishing whether allergic disease causes mental health problems, or vice versa, is important to ensure that treatment resources and strategies are targeted appropriately,” said study author Hannah Sallis, PhD, MSc, University of Bristol in England. (Clinical and experimental allergy)

A 19-year-old has been admitted to a mental hospital after throwing an egg at the head of French President Emmanuel Macron during an international food festival. (New York Post)

Bills in Congress allocated $ 237.8 million in federal funds to build a state mental hospital in Dallas that would be operated by UT Southwestern Medical Center. (Dallas Morning News)

Phase III results showing that treatment with 42 mg per day of lumateperone (Caplyta) resulted in a significant reduction in depressive symptoms compared to placebo in patients with a major depressive episode associated with bipolar I / II disorder come from be published in the journal American Journal of Psychiatry, announced drug maker Intra-Cellular Therapies. Although approved for schizophrenia, the FDA is currently reviewing the atypical antipsychotic for bipolar depression, with a PDUFA target action date of December 17, 2021.

Thomas Laughren, MD, the former FDA director for the Psychiatric Products Division, is moving to PharmaTher Holdings as the new Regulatory Affairs Advisor; he will oversee business with Ketabet, the company’s combination ketamine and betaine therapy.

  • Kristen Monaco is editor-in-chief, specializing in news in endocrinology, psychiatry and nephrology. Based in the New York office, she has been with the company since 2015.


Source link

Leave A Reply

Your email address will not be published.